NCT03714308View on ClinicalTrials.gov

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.

CompletedOBSERVATIONAL
Enrollment

554

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

March 6, 2023

Study Completion Date

May 12, 2023

Conditions
Macular Degeneration
Interventions
DRUG

Ivt. Aflibercept (Eylea, BAY86-5321)

Treatment is applied according to routine clinical practice and independent of the study setting.

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03714308 - Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina. | Biotech Hunter | Biotech Hunter